profit from every $100 of sales.
$0$100
Lineage Cell Therapeutics
$1.11+6.73% today
-39.0% in 1 year
1-year low $0.901-year high $1.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Lineage Cell Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $14.7 million in 2022 to $14.6 million in 2025, with -$63.5 million of profit last year.
SalesProfit
Lineage Cell Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lineage Cell Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Lineage Cell Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 15 | 9 | 9 | 15 | |
| 14 | 8 | 9 | 14 | |
| -23 | -25 | -21 | -22 | |
| -22 | -24 | -21 | -21 | |
| -26 | -21 | -19 | -64 | |
| -0.15 | -0.12 | -0.09 | -0.28 | |
| 95.0% | 92.5% | 96.5% | 99.0% | |
| -153.2% | -276.5% | -226.1% | -149.6% | |
| -178.7% | -240.2% | -195.9% | -436.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 124 | 101 | 113 | 113 |
| Cash | 11 | 35 | 46 | 41 |
| Total debt | 4 | 3 | 3 | 2 |
| Total liabilities | 52 | 39 | 36 | 69 |
| 73 | 63 | 78 | 45 | |
| 170 | 173 | 200 | 230 | |
| -23.0% | -29.4% | -21.0% | -36.6% | |
| -35.8% | -33.9% | -23.7% | -142.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | -29 | -23 | -19 | |
| 0 | 1 | 1 | 1 | |
| 1 | -29 | -24 | -19 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | 0 | 0 | |
| 4 | 5 | 5 | 5 |
Valuation
- –
- –
- –
- 5.5×
- 19.3×
- –
- –
- -6.9%
- -22.6%
- 0.0%
Profitability
- 99.0%
- -149.6%
- -436.5%
- -325.5%
- -34.1%
- -54.0%
- -152.1%
- -58.6%
- -37.2%
- 127.5%
Growth
- −0.3%
- –
- +17.8%
- –
- +8.8%
Financial health
- -1.8×
- 0.04
- 2.2%
- –
- 6.89
- 6.89
- 0.13
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 958
Bottom 2%of 888
Bottom 17%of 889
Bottom 13%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.03 | -0.02 | −50.0% |
| Mar 5, 2026 | 0.00 | -0.04 | +109.2% |
| Nov 6, 2025 | -0.13 | -0.02 | −550.0% |
| Aug 12, 2025 | -0.01 | -0.02 | +50.0% |
| May 13, 2025 | -0.02 | -0.02 | +0.0% |
| Mar 10, 2025 | -0.01 | -0.04 | +75.0% |
| Nov 14, 2024 | -0.02 | -0.01 | −53.5% |
| Aug 8, 2024 | -0.03 | -0.05 | +40.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
42No pass
Philip Fisher
33No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
27No pass
Questions about Lineage Cell Therapeutics
Is Lineage Cell Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lineage Cell Therapeutics AI analysis
What does Lineage Cell Therapeutics do?
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. It is in Biotechnology.
Does Lineage Cell Therapeutics pay a dividend?
No. Lineage Cell Therapeutics does not pay a dividend at the moment; in 2025 it returned $16,000 to shareholders by buying back its own shares.
Is Lineage Cell Therapeutics stock halal?
Yes. Lineage Cell Therapeutics passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has Lineage Cell Therapeutics stock done over the past year?
Down 39.0% over the past twelve months, to $1.11. It traded between $0.90 and $1.96 and is 43.4% below its high.
Who are Lineage Cell Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Lineage Cell Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.